Evidence map›Paper›PMID 41350277›Full record

ArticleNPJ vaccines2025

Cross-herpesvirus immunity of the cytomegalovirus gB/MF59 vaccine response.

A Lankina, A Hargreaves, W T Lui, B Kropff, A Wei, J Breuer, R E White, M Thomas, P D Griffiths, M B Reeves

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

A LankinaInstitute of Immunity and Transplantation, University College London, London, UK.
A HargreavesInstitute of Immunity and Transplantation, University College London, London, UK.
W T LuiInstitute of Immunity and Transplantation, University College London, London, UK.
B KropffVirologisches Institut, Klinische und Molekulare Virologie, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
A WeiInstitute of Immunity and Transplantation, University College London, London, UK.
J BreuerGreat Ormond Street Institute of Child Health, University College London, London, UK.
R E WhiteDepartment of Infectious Disease, Imperial College London, London, UK.
M ThomasVirologisches Institut, Klinische und Molekulare Virologie, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
P D GriffithsInstitute of Immunity and Transplantation, University College London, London, UK.
M B ReevesInstitute of Immunity and Transplantation, University College London, London, UK. matthew.reeves@ucl.ac.uk.

Funding

Biotechnology and Biological Sciences Research Council BB/T008709/1Kidney Research UK RP_008_20231101Medical Research Council MR/W006774/1Wellcome TrustWellcome Trust WT/204870/Z/16/Z
6 · The paper itself

Abstract

Vaccination against human cytomegalovirus (HCMV) to protect transplant recipients and prevent congenital infection remains highest priority. Follow-up analyses of a vaccine directed against the fusion protein glycoprotein B (gB/MF59) identified a vaccine-specific response (AD-6) that correlated with protection. Subsequently, it was demonstrated that AD-6 antibodies are anti-viral by preventing cell-associated spread. Here we now demonstrate AD-6 antibodies limit HCMV reactivation - an event critical for pathogenesis via hematogenic spread in vivo. To better understand the AD-6 immunogen, we use structural homology to identify putative AD-6 regions in related herpesviruses and show, despite limited sequence similarity, they share key physico-chemical properties. Of note was that AD-6 mapped to a region under high molecular frustration within gB - arguing AD-6 antibodies inhibit gB function by targeting activity dependent on conserved conformational changes. Consistent with structural conformation being crucial, we observe that both rabbit and human HCMV AD-6 antibodies recognise other herpesvirus AD-6s and that AD-6 antibodies are potently antiviral against HSV-1. Thus, a combinatorial in silico, biochemical and immunological approach reveals conformational epitopes within AD-6 are critical components of the gB/MF59 vaccine, represent crucial conserved elements of AD-6 in gB structure and function which makes it an attractive target of multiple herpesviruses.

Identifiers

PMID41350277
PMCPMC12680769

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.